Patritumab deruxtecan (anti-ERBB3) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity. Purity >90% (SDS-PAGE&SEC) Endotoxin Level < 1.0EU/mg
Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂
No
储存条件
-80℃储存,避免反复冻融
运输条件
特低温运输
稳定性与储存
在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
图片
Patritumab deruxtecan (anti-ERBB3) (Ab183315) - Flow Cytometry Flow Cytometry analysis of MCF-7 cells labelling ERBB3 (red) with Patritumab deruxtecan (anti-ERBB3) (Ab183315). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Patritumab deruxtecan (anti-ERBB3) (Ab183315) - Flow Cytometry Flow Cytometry analysis of A431 cells labelling ERBB3 (red) with Patritumab deruxtecan (anti-ERBB3) (Ab183315). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Patritumab deruxtecan (anti-ERBB3) (Ab183315) - ELISA Immobilized Recombinant Human ERBB3 protein (rp170123) at 1.0 μg/mL can bind Patritumab deruxtecan (anti-ERBB3) (Ab183315) with the EC₅₀ of 24.89 ng/mL.
Patritumab deruxtecan (anti-ERBB3) (Ab183315) - SEC The purity of Patritumab deruxtecan (anti-ERBB3) (Ab183315) is more than 95% verified by HPLC.